Video

Dr. Soares on the Standard of Care in Metastatic Pancreatic Cancer

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Heloisa P. Soares, MD, PhD, medical oncologist, assistant professor, Huntsman Cancer Institute, University of Utah, discusses the standard of care in metastatic pancreatic cancer.

Currently, in the treatment landscape for locally advanced metastatic pancreatic cancer, 2chemotherapy regimens are available, Soares explains. The standard options include FOLFIRINOX and gemcitabine plus nab-paclitaxel (Abraxane). No study has compared these regimens head-to-head, which makes selecting between them challenging. Moreover, FOLFIRINOX is typically reserved for patients with good ECOG performance status, Soares says.

Ultimately, gemcitabine and nab-paclitaxel are favored compared with FOLFIRINOX because the doublet is better tolerated, Soares concludes.

Related Videos
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.